Pharmsintez began registration in Russia of the drug Epolong for the treatment of anemia in patients with chronic kidney disease. The drug is being developed jointly with the Serum Institute of India and the American biopharmaceutical company Xenetic Biosciences. It is expected that the Russian stage of registration activities will be completed in 2021 and the company will be able to start production of the drug as early as Q1 2022.